Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Ранг среди акций #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Цена акции
$0.25974701
Последняя синхронизация: 2025-01-06
Рыночная капитализация
$2.04M
Изменение (1 день)
0.74%
Изменение (1 год)
0.00%
Страна
FR
Торговля Acticor Biotech SAS (ALACT)

Категория

EPS для Acticor Biotech SAS (ALACT)
EPS по состоянию на June 2024 TTM: $-1.95
Согласно последним финансовым отчетам и цене акций Acticor Biotech SAS, текущий EPS компании (TTM) составляет $-1.95. В конце 2022 EPS компании составлял $-1.62, меньше, чем показателю 2021 года, равному $-1.84.
История EPS компании Acticor Biotech SAS с 2010 по 2026
EPS на конец каждого года
Год EPS Изменить
2026 (TTM) $-1.95 -99.90%
2023 0.00 -99.90%
2022 $-1.62 -12.08%
2021 $-1.84 26.05%
2020 $-1.46 35.69%
2019 $-1.08 -51.93%
2018 $-2.24 -40.33%
2017 $-3.76 2,449.69%
2016 $-0.15 -66.91%
2015 $-0.45 26.87%
2014 $-0.35 -143.25%
2013 $0.81 -9.55%
2012 $0.90 35.87%
2011 $0.66 462.35%
2010 $0.12 0.00%
EPS для аналогичных компаний или конкурентов
Компания EPS Разница в EPS Страна
$17.32 -986.39%
US
$27.74 -1,519.65%
NL
$-5.29 170.73%
AU
$-7.98 308.39%
US
- -
CH